Tags

Type your tag names separated by a space and hit enter

Evaluation of the tolerability and efficacy of Sativex in multiple sclerosis.
Expert Rev Neurother. 2014 Nov; 14(11):1243-50.ER

Abstract

Refractory spasticity, central neuropathic pain and bladder dysfunction are common clinical problems in patients with multiple sclerosis (MS). None of the currently available oral medications has proven to be reliably effective and can be limited by toxicity. Cannabinoids have shown therapeutic effects on those MS-associated symptoms. Delta-9-tetrahydrocannabinol (THC)/cannabidiol (CBD) Sativex (nabiximols) is an oromucosal spray formulation that contains THC and CBD in an approximate 1:1 ratio and is described as an endocannabinoid system modulator. The efficacy of THC/CBD on MS-associated spasticity, pain and bladder dysfunction has been studied in clinical trials as well as in clinical practice studies. Adverse effects are usually mild or moderate and the low rate of drug discontinuation provides good evidence of long-term tolerability. This article focuses on the pharmacological properties, clinical efficacy and tolerability of THC/CBD in MS patients.

Authors+Show Affiliations

Hospital Universitario Puerta de Hierro, Laboratorio de Neuroinmunologia, Majadahonda, 28222, Spain.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

25331416

Citation

Moreno Torres, Irene, et al. "Evaluation of the Tolerability and Efficacy of Sativex in Multiple Sclerosis." Expert Review of Neurotherapeutics, vol. 14, no. 11, 2014, pp. 1243-50.
Moreno Torres I, Sanchez AJ, Garcia-Merino A. Evaluation of the tolerability and efficacy of Sativex in multiple sclerosis. Expert Rev Neurother. 2014;14(11):1243-50.
Moreno Torres, I., Sanchez, A. J., & Garcia-Merino, A. (2014). Evaluation of the tolerability and efficacy of Sativex in multiple sclerosis. Expert Review of Neurotherapeutics, 14(11), 1243-50. https://doi.org/10.1586/14737175.2014.971758
Moreno Torres I, Sanchez AJ, Garcia-Merino A. Evaluation of the Tolerability and Efficacy of Sativex in Multiple Sclerosis. Expert Rev Neurother. 2014;14(11):1243-50. PubMed PMID: 25331416.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Evaluation of the tolerability and efficacy of Sativex in multiple sclerosis. AU - Moreno Torres,Irene, AU - Sanchez,Antonio J, AU - Garcia-Merino,Antonio, PY - 2014/10/22/entrez PY - 2014/10/22/pubmed PY - 2015/6/25/medline KW - Sativex KW - cannabinoids KW - central neuropathic pain KW - multiple sclerosis KW - nabiximols KW - spasticity SP - 1243 EP - 50 JF - Expert review of neurotherapeutics JO - Expert Rev Neurother VL - 14 IS - 11 N2 - Refractory spasticity, central neuropathic pain and bladder dysfunction are common clinical problems in patients with multiple sclerosis (MS). None of the currently available oral medications has proven to be reliably effective and can be limited by toxicity. Cannabinoids have shown therapeutic effects on those MS-associated symptoms. Delta-9-tetrahydrocannabinol (THC)/cannabidiol (CBD) Sativex (nabiximols) is an oromucosal spray formulation that contains THC and CBD in an approximate 1:1 ratio and is described as an endocannabinoid system modulator. The efficacy of THC/CBD on MS-associated spasticity, pain and bladder dysfunction has been studied in clinical trials as well as in clinical practice studies. Adverse effects are usually mild or moderate and the low rate of drug discontinuation provides good evidence of long-term tolerability. This article focuses on the pharmacological properties, clinical efficacy and tolerability of THC/CBD in MS patients. SN - 1744-8360 UR - https://www.unboundmedicine.com/medline/citation/25331416/Evaluation_of_the_tolerability_and_efficacy_of_Sativex_in_multiple_sclerosis_ L2 - http://www.tandfonline.com/doi/full/10.1586/14737175.2014.971758 DB - PRIME DP - Unbound Medicine ER -